Advertisement
U.S. markets closed

Trevi Therapeutics, Inc. (TRVI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.4500-0.0200 (-0.58%)
At close: 04:00PM EDT
3.4500 0.00 (0.00%)
After hours: 04:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close3.4700
Open3.4700
Bid3.4300 x 200
Ask3.4800 x 100
Day's Range3.3900 - 3.5400
52 Week Range0.9700 - 4.0000
Volume112,736
Avg. Volume279,526
Market Cap237.913M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TRVI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Trevi Therapeutics, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • PR Newswire

    Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter and year ended December 31, 2023, as well as provided business updates.

  • PR Newswire

    Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, March 20, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended

  • PR Newswire

    Trevi Therapeutics to Participate in Upcoming March Events

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will attend and participate in the following events in March.